Make Better Decisions - Finding and Evaluating Generic and Branded Drug Market Entry Opportunities

Get the Book: Make Better Decisions

Finding and Evaluating Generic and Branded Drug Market Entry Opportunities

PDF eBook: Just $10 Get Print Book on Amazon

Serving hundreds of leading biopharmaceutical companies globally:

Express Scripts
Healthtrust
Colorcon
Fuji
Argus Health
Queensland Health

Generated: August 24, 2019

DrugPatentWatch Database Preview

Patent: 7,904,162

  Try a free trial


See Plans and Pricing

« Back to Dashboard

Summary for Patent: 7,904,162
Title:Monitoring, preventing, and treating rejection of transplanted organs
Abstract: An implantable system control unit (SCU) includes means for measuring tissue impedance or other condition to determine allograft health, in order to predict or detect allograft rejection. The SCU also includes at least two electrodes coupled to means for delivering electrical stimulation to a patient within whom the device is implanted, and may also include a reservoir for holding one or more drugs and a driver means for delivering the drug(s) to the patient. In certain embodiments, the system is capable of open- and closed-loop operation. In closed-loop operation, at least one SCU includes a sensor, and the sensed condition is used to adjust stimulation parameters. Alternatively, this sensory \"SCU\" sounds an alarm, communicates an alarm to an external device, and/or is responsive to queries regarding sensed information, such as tissue impedance.
Inventor(s): Whitehurst; Todd K (Santa Clarita, CA), McGivern; James P (Stevenson Ranch, CA), McClure; Kelly H (Simi Valley, CA), Marnfeldt; Goran N (Hollviken, SE), Thacker; James R (Eureka, MO)
Assignee: Boston Scientific Neuromodulation Corporation (Valencia, CA)
Application Number:11/246,719
Patent Claims:see list of patent claims

Details for Patent 7,904,162

Applicant Tradename Biologic Ingredient Dosage Form BLA Number Approval Date Patent No. Assignee Estimated Patent Expiration Status Orphan Source
Biogen ZINBRYTA daclizumab INJECTABLE;INJECTION 761029 001 2016-05-27 ➤ Sign Up Boston Scientific Neuromodulation Corporation (Valencia, CA) 2021-09-18 RX search
Novartis SIMULECT basiliximab VIAL; SINGLE-USE 103764 002 1998-05-12 ➤ Sign Up Boston Scientific Neuromodulation Corporation (Valencia, CA) 2021-09-18 RX search
Novartis SIMULECT basiliximab VIAL; SINGLE-USE 103764 001 1998-05-12 ➤ Sign Up Boston Scientific Neuromodulation Corporation (Valencia, CA) 2021-09-18 RX search
>Applicant >Tradename >Biologic Ingredient >Dosage Form >BLA >Number >Approval Date >Patent No. >Assignee >Estimated Patent Expiration >Status >Orphan >Source

Subscribe to access the full database, or try a Free Trial

Make Better Decisions: Try a trial or see plans & pricing

Serving hundreds of leading biopharmaceutical companies globally:

Queensland Health
Healthtrust
Covington
AstraZeneca
Accenture
UBS

Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors. Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data. The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free. thinkBiotech performs no independent verifification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user. Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.